Next Article in Journal
Mechanisms of Disease in Sjögren Syndrome—New Developments and Directions
Next Article in Special Issue
Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models
Previous Article in Journal
Identification of a Novel Linear B-Cell Epitope on the Nucleocapsid Protein of Porcine Deltacoronavirus
Previous Article in Special Issue
Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model
Open AccessReview

MicroRNAs in Vascular Eye Diseases

Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(2), 649; https://doi.org/10.3390/ijms21020649
Received: 27 December 2019 / Accepted: 16 January 2020 / Published: 19 January 2020
Since the discovery of the first microRNA (miRNA) decades ago, studies of miRNA biology have expanded in many biomedical research fields, including eye research. The critical roles of miRNAs in normal development and diseases have made miRNAs useful biomarkers or molecular targets for potential therapeutics. In the eye, ocular neovascularization (NV) is a leading cause of blindness in multiple vascular eye diseases. Current anti-angiogenic therapies, such as anti-vascular endothelial growth factor (VEGF) treatment, have their limitations, indicating the need for investigating new targets. Recent studies established the roles of various miRNAs in the regulation of pathological ocular NV, suggesting miRNAs as both biomarkers and therapeutic targets in vascular eye diseases. This review summarizes the biogenesis of miRNAs, and their functions in the normal development and diseases of the eye, with a focus on clinical and experimental retinopathies in both human and animal models. Discovery of novel targets involving miRNAs in vascular eye diseases will provide insights for developing new treatments to counter ocular NV. View Full-Text
Keywords: AMD: biomarker; eye disease; retinopathy; neovascularization; microRNA AMD: biomarker; eye disease; retinopathy; neovascularization; microRNA
Show Figures

Figure 1

MDPI and ACS Style

Liu, C.-H.; Huang, S.; Britton, W.R.; Chen, J. MicroRNAs in Vascular Eye Diseases. Int. J. Mol. Sci. 2020, 21, 649.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop